Quantcast

Latest Biosimilar Stories

2014-06-18 04:21:25

Change in regulatory frameworks and standards are essential to expedite approval and release of innovative products LONDON, June 18, 2014 /PRNewswire/ -- Regenerative medicine has the potential to transform healthcare all over the world and usher human health into a new era of wellness. Currently, the majority of treatments for chronic and fatal diseases is palliative or to delay disease progression; in contrast, regenerative medicine is uniquely capable of altering the underlying...

2014-06-16 23:04:54

GIA announces the release of a comprehensive global report on Human Growth Hormone Drugs markets. Global market for Human Growth Hormone (hGH) Drugs is forecast to reach US$3.8 billion by 2020, spurred by progressive increase in the prevalence of growth hormone deficiency diseases, impending patent expiries of major hGH drugs, and emergence of novel drug formulations and drug-delivery systems. San Jose, California (PRWEB) June 16, 2014 Follow us on LinkedIn. – Demand for safer and...

2014-06-11 16:24:35

RnRMarketResearch.com adds "Next-Generation Biologics R&D, Industry and Market 2014-2024" on its store. Order a purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=185532 . DALLAS, June 11, 2014 /PRNewswire-iReach/ -- Next-generation biologics will address shortcomings in current therapies, including inconvenient dosing and concerns over side effects. Developmental trends include sustained release, for less-frequent dosing, and reformulations for oral and topical...

2014-06-09 20:22:33

- Terms Unchanged from Previously Disclosed Agreement - DUBLIN, June 9, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has finalized its previously announced agreement with Zydus Pharmaceuticals USA Inc. to settle all outstanding patent litigation related to Zydus' generic version of Asacol(®) HD (mesalamine) delayed-release tablets. The terms of the agreement are unchanged from those disclosed by the companies in December 2013. Under the terms of the...

2014-06-09 14:39:26

Health Affairs Reducing Maternal Mortality In Zambia and Uganda. Margaret E. Kruk of Columbia University and co-authors assessed the effectiveness of Saving Mothers, Giving Life, a new global public-private partnership that aims to reduce maternal mortality in eight districts in Uganda and Zambia. They evaluated the first six to twelve months of the program's implementation, its ownership by national ministries of health, and its effects on health systems. According to the authors, early...

2014-06-09 08:29:01

REDWOOD CITY, Calif., June 9, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. ("Coherus"), is pleased to announce the appointment of Vince R. Anicetti as Senior Vice President, Global Quality. Mr. Anicetti joins Coherus with more than 30 years of experience in quality and regulatory affairs at preeminent biotech companies. "Vince's breadth and depth of experience will be critical to delivering to patients high-quality biosimilars with robust consistency," said Denny Lanfear,...

2014-06-04 08:33:48

WASHINGTON, June 4, 2014 /PRNewswire-USNewswire/ -- In a letter submitted today to the U.S. Food and Drug Administration (FDA), the National Organization for Rare Disorders (NORD) urged Commissioner Margaret Hamburg to give serious consideration to the concerns of the rare disease community when setting policy regarding official names for biologics, including biosimilars. With over 7,000 rare diseases identified and 30 million Americans affected, the patient population represented by NORD is...

2014-06-03 23:03:26

Regulating Biosimilars; Stem Cell Therapies and 3-D Printing; Increasing FDA Oversight Overseas Washington (PRWEB) June 03, 2014 Hot topics facing drug development and access—evolving regulatory guidelines for novel therapies, a shifting pharmaceutical research and development (R&D) landscape, and U.S. regulatory challenges at home and overseas—will be discussed by global innovators at the DIA 2014 50th Annual Meeting, to be held at the San Diego Convention Center from June 15 to...

2014-06-02 08:31:48

CRANBURY, N.J., June 2, 2014 /PRNewswire/ -- Ipca Laboratories Ltd., India (Ipca) and Oncobiologics, Inc., USA (Oncobiologics) announced today the creation of a two-part alliance for the development, manufacture and commercialization of biosimilar monoclonal antibody products. Under the first part of the agreement, Ipca will in-license and commercialize biosimilar products for the India and associated markets. These products will be developed by Oncobiologics to US FDA and EU...

2014-05-27 23:13:40

In an upcoming webinar from Atlantic Information Services, participants will learn how to manage specialty drug coupons without compromising patient access. Washington, DC (PRWEB) May 27, 2014 As the biologics pipeline continues to grow and patients face increasing specialty copays, co-insurance and maximum out-of-pocket limits, manufacturer-offered specialty drug coupons are becoming more commonplace. And with biosimilars soon entering the market, it will be critical for payers to...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.